PureID Medical Technology, a global-leading SaaS+Data life science provider, will continue to upgrade its global regulation intelligence platform and help medical device companies license-out their products with the fresh proceeds.
xx
PureID Medical Technology (Chinese: 普瑞纯证) announced its completion of the Series B round of financing worth more than CNY 100 million recently. The round was led by Legend Capital (Chinese: 君联资本), with the participation from the existing shareholder Bayland Capital (Chinese: 康君资本). Probe Capital (Chinese: 探针资本) served as the exclusive financial advisor for this round.
The funds will be used for the layout of overseas medical device resources, expansion of the professional talent team, strategic expansion in the medical device field, and upgrade and iteration of the big data information platform.
Founded in 2020, PureID is a global-leading SaaS+Data life science provider which focuses on whole-process informatization of medical devices going abroad in the global market. Besides, the company is dedicated to providing the whole-process consulting services for compliance access to the global market for medical devices, in vitro diagnostics and medical software AI products.
The company's service network has spread to 10 countries and regions worldwide, including the United States, Germany, Italy, Spain, Switzerland and Poland. Moreover, it has been doing business with over 100 domestic and international medical and biotech companies, and has been widely recognized by industry insiders.
The company's competitors include OSMUNDA (Chinese: 奥咨达), Share Info (Chinese: 捷闻医械) and Medical Strong (Chinese: 迈迪思创).
The Billion-Dollar European Caviar Business, Now Disrupted by China
Nov 08, 2024 01:52 PM
Forty Years of Striving: How Globalization Has Shaped Lenovo Today?
Nov 07, 2024 06:51 PM